Estradiol benzoate butyrate/algestone acetophenide
{{Short description|Combination drug}}
{{Drugbox
| image = Estradiol butyrate benzoate.svg
| width = 250px
| caption =
| image2 = Algestone acetophenide.svg
| width2 = 235px
| caption2 = Estradiol benzoate butyrate (top) and
algestone acetophenide (bottom)
| type = combo
| drug_name = Estradiol benzoate butyrate /
algestone acetophenide
| component1 = Estradiol benzoate butyrate
| class1 = Estrogen
| component2 = Algestone acetophenide
| class2 = Progestogen
| tradename = Neolutin N, Redimen, Soluna, Unijab
| Drugs.com =
| MedlinePlus =
| licence_EU =
| licence_US =
| DailyMedID =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration = Intramuscular injection
| CAS_number =
| CAS_supplemental =
| ATCvet =
| ATC_prefix =
| ATC_suffix =
| ATC_supplemental =
| PubChem =
| PubChemSubstance =
| IUPHAR_ligand =
| DrugBank =
| ChemSpiderID =
| UNII =
| KEGG =
| ChEBI =
| ChEMBL =
| synonyms = Estradiol benzoate butyrate/dihydroxyprogesterone acetophenide; EBB/DHPA; Unimens
}}
Estradiol benzoate butyrate/algestone acetophenide, also known as estradiol benzoate butyrate/dihydroxyprogesterone acetophenide (EBB/DHPA) and sold under the brand names Neolutin N, Redimen, Soluna, and Unijab, is a form of combined injectable birth control which is used in Peru and Singapore.{{cite journal | vauthors = Toppozada M | title = The clinical use of monthly injectable contraceptive preparations | journal = Obstet Gynecol Surv | volume = 32 | issue = 6 | pages = 335–47 | date = June 1977 | pmid = 865726 | doi = 10.1097/00006254-197706000-00001 }}{{cite book|author1=IARC Working Group on the Evaluation of Carcinogenic Risks to Humans|author2=World Health Organization|author3=International Agency for Research on Cancer|title=Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy|url=https://books.google.com/books?id=aGDU5xibtNgC&pg=PA433|year=2007|publisher=World Health Organization|isbn=978-92-832-1291-1|pages=433, 467}}{{cite book|author1=IARC Working Group on the Evaluation of Carcinogenic Risks to Humans|author2=International Agency for Research on Cancer|title=Hormonal Contraception and Post-menopausal Hormonal Therapy|date=1 January 1999|publisher=IARC|isbn=978-92-832-1272-0|page=65|url=https://monographs.iarc.fr/wp-content/uploads/2018/06/mono72.pdf|access-date=16 September 2018|archive-date=28 August 2021|archive-url=https://web.archive.org/web/20210828080855/https://monographs.iarc.who.int/wp-content/uploads/2018/06/mono72.pdf|url-status=dead}}{{cite web|url=https://www.datosperu.org/farmaco-soluna-rs-N12759.php|title=Farmaco SOLUNA 150 + 10 registrado en Perú}}{{cite web|url=http://www.mims.com/singapore/drug/info/unijab|title = Unijab Dosage & Drug Information | MIMS Singapore}}{{cite web |url=http://www.corporacionmisalud.com/sistema/vademecum/PLM/productos/32499.htm |title=SOLUNA |website=www.corporacionmisalud.com |url-status=dead |archive-url=https://web.archive.org/web/20141005184908/http://corporacionmisalud.com/sistema/vademecum/PLM/productos/32499.htm |archive-date=2014-10-05}} It contains estradiol benzoate butyrate (EBB), an estrogen, and algestone acetophenide (dihydroxyprogesterone acetophenide; DHPA), a progestin. The medication is given once per month by injection into muscle.
Medical uses
EBB/DHPA is used as a once-a-month combined injectable contraceptive to prevent pregnancy in women.
=Available forms=
EBB/DHPA contains 10 mg estradiol benzoate butyrate (EBB), an estrogen, and 150 mg algestone acetophenide (dihydroxyprogesterone acetophenide; DHPA), a progestin.
Pharmacology
=Pharmacodynamics=
EBB/DHPA has been said to have relatively weak estrogenic activity and has been described as "progestogen-dominant".
=Pharmacokinetics=
EBB is said to have a shorter duration than estradiol enantate of about 3 weeks.{{cite book | author = Mokhtar K. Toppozada | chapter = Monthly Injectable Contraceptives | pages = 93–103 | editor1 = Alfredo Goldsmith | editor2 = Mokhtar Toppozada | title = Long-Acting Contraception | year = 1983 | oclc = 35018604 | url = https://scholar.google.com/scholar?cluster=14664537528797672080}} EBB/DHPA was developed because it was thought that the duration of EBB would be more suitable for use as a once-monthly combined injectable contraceptive than estradiol enantate in estradiol enantate/algestone acetophenide.
Society and culture
=Brand names=
EBB/DHPA is marketed under the brand names Neolutin N, Redimen, Soluna, and Unijab.{{Cite web |url=https://www.drugs.com/international/soluna.html |title=Archived copy |access-date=2019-02-25 |archive-date=2019-02-25 |archive-url=https://web.archive.org/web/20190225103155/https://www.drugs.com/international/soluna.html |url-status=dead }} It was originally developed under the tentative brand name Unimens, but ultimately was not marketed under this particular brand name.{{cite book|author=Elsayed Saad Eldin Hafez|title=Human reproduction: conception and contraception|url=https://books.google.com/books?id=EblsAAAAMAAJ|year=1980|publisher=Harper and Row|isbn=978-0-06-141066-6}}{{cite journal | vauthors = Newton JR, D'arcangues C, Hall PE | title = A review of "once-a-month" combined injectable contraceptives | journal = J Obstet Gynaecol (Lahore) | volume = 4 Suppl 1 | pages = S1–34 | year = 1994 | pmid = 12290848 | doi = 10.3109/01443619409027641}}{{cite journal | vauthors = Toppozada MK | title = Existing once-a-month combined injectable contraceptives | journal = Contraception | volume = 49 | issue = 4 | pages = 293–301 | date = April 1994 | pmid = 8013216 | doi = 10.1016/0010-7824(94)90029-9 }}
=Availability=
See also
References
{{Reflist}}
{{Birth control methods}}
{{Hormonal contraceptives}}
{{Estrogen receptor modulators}}
{{Progesterone receptor modulators}}
{{Portal bar|Medicine}}
{{DEFAULTSORT:Estradiol benzoate butyrate algestone acetophenide}}